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Abstract
Background: Celiac disease is a multi-system disorder with manifestations that may result in psychiatric disorders.
We assessed the prevalence of medication use to treat psychiatric disorders in celiac disease patients.
Methods: We conducted a cross-sectional study of patients undergoing esophagogastroduodenoscopy over
9-years at a celiac disease referral center. We compared the prevalence of psychotropic medication use among
celiac disease patients (n = 1293) to a control group (n = 1401) with abdominal pain or reflux.
Results: Among all patients the mean age was 48.4 years, most were female (69.5%), and 22.7% used any psychotropic
medication. There was no difference between overall psychotropic medication use among celiac disease patients and
controls (23.9% vs 21.8%, OR 1.16; 95% CI 0.96–1.39, p = 0.12). However, those with celiac disease were more likely to use
antidepressants on univariate (16.4% vs 13.4%, p = 0.03) and multivariate analysis (OR 1.28; 95% CI 1.03–1.59; p = 0.03).
Use of psychotropic medications was not associated with disease duration or mode of presentation of celiac disease.
Conclusions: Celiac disease patients use psychotropic medications at similar rates as those with other gastrointestinal
diseases, though subgroup analysis suggests they may use more antidepressants. Future studies should investigate
whether celiac disease is associated with mood disorders that are not treated with medications.
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Background
Celiac Disease affects up to 1% of the general population
worldwide [1]. In addition to gastrointestinal symptoms
and sequelae of malabsorption, celiac disease is character-
ized by extraintestinal manifestations including neurological
and psychiatric disorders [2, 3]. There is uncertainty regard-
ing the nature of the relationship between psychiatric
illnesses and celiac disease. The reported prevalence of
depression in celiac disease has varied widely, ranging
from 6% to 57% [4–12], with some studies showing a
positive association between celiac disease and depression
[4–6, 8, 9, 11, 13–19], others showing no association
[7, 10, 20–22], and still others showing no difference
compared to other chronic diseases [9, 10, 18, 21]. Anxiety
has been associated with celiac disease in some stud-
ies [4, 5, 13, 14], while others found no association
[7, 10, 18, 23]. Even fewer studies have addressed the
association between celiac disease and attention deficit
hyperactivity disorder [10, 24], bipolar disorder [10, 17, 19],
and fatigue [11, 25, 26].
Many of these studies have been limited by small sample
sizes [4–6, 8, 9, 11, 13–16, 19, 20, 22–24, 26–29], with only
a few [7, 10, 12, 17, 21, 25] including more than 200 celiac
disease subjects. Furthermore, only one of these studies
was performed in the United States [10]. In order to assess
the prevalence of psychiatric disorders we assessed the
prevalence of medication use to treat psychiatric disorders
among patients with celiac disease undergoing endoscopy
in a North American setting.
Methods
In this cross-sectional study, we used an electronic en-
doscopy database to search all patients aged at least
18 years undergoing outpatient esophagogastroduode-
noscopy (EGD) during a 9-year period from January 1st
2007 to Dec 31st 2015 performed at Columbia Univer-
sity Medical Center, a hospital-based endoscopy suite
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in New York City. The presence of celiac disease was
defined based on endoscopy reports whose listed EGD
indication was either evaluation of suspected celiac disease
(with duodenal biopsy showing villous atrophy) or follow-
up evaluation of celiac disease. We then identified a con-
trol population consisting of individuals undergoing EGD
for the indications of gastroesophageal reflux disease
(GERD) or for abdominal pain (including dyspepsia).
To minimize underlying sociodemographic differences
between the celiac disease patients and controls, we
limited our inclusion criteria to endoscopies performed
by the six gastroenterologists affiliated with the Celiac
Disease Center at Columbia University, a major referral
center for the diagnosis and management of celiac dis-
ease. As is routine practice before endoscopic proce-
dures, all patients underwent a pre-procedure interview
with a nurse where the patient was directly asked to list
all current outpatient medications. The medications
gathered in these interviews were the only medications
used in our analysis.
For our primary exposure of interest, we compared the
prevalence of any psychotropic medication use in celiac
disease patients to controls. We then examined individual
classes of psychotropic medications, including antidepres-
sants, anti-psychotics, anxiolytics, mood stabilizers, sleep
aids, and sympathomimetics (see appendix). As a second-
ary outcome, we divided patients with celiac disease ac-
cording to disease duration and mode of presentation
(classical symptoms of malabsorption compared to non-
classical or asymptomatic cases, as previously defined in
the literature) [30] so as to determine whether duration of
treatment after diagnosis, as well as symptoms at the
onset of diagnosis, were associated with psychotropic
medication use. We calculated disease duration when date
of celiac disease diagnosis was available among patient
records in our prospectively-maintained celiac disease
patient database.
We used the chi square and Fisher exact tests to com-
pare proportions and calculate p-values and we used
multivariate logistic regression, adjusting for age and sex,
to calculate odds ratios (ORs) and their 95% Confidence
Intervals (CIs), reporting measures of association between
psychotropic medication use and the variables of interest.
We also performed multiple logistic regression, adjusting
for age and sex, to quantify the association between psy-
chotropic medication use in patients with celiac disease
and duration of celiac disease as well as mode of presenta-
tion. All reported p values are 2-sided. We used SAS ver-
sion 9.4 (Cary, NC) for all analyses. Columbia University
Medical Center’s Institutional Review Board approved this
study, IRB-AAAQ9855, on August 9th 2016, asserting that
this study met all ethical guidelines. As this study included
data that had already been collected, informed consent
was not deemed necessary.
Results
During the nine-year period of the study, 1293 patients
underwent EGD for celiac disease by 6 providers at the
Celiac Disease Center at Columbia University. During this
time period, 811 and 590 non-celiac patients underwent
endoscopy by those providers for evaluation of abdominal
pain and GERD, respectively. Demographic information is
shown in Table 1. The mean age of the entire sample was
48.37 years. Celiac disease patients had a lower mean age
compared to controls (44.9 years vs 51.6 years, p < 0.
0001). Females made up 70% of our population and were
the dominant sex in both groups, though a larger percent-
age of patients with celiac disease were female (73% vs
66%, p = 0.0003).
A comparison of psychotropic medication use in patients
with celiac disease compared to controls is shown in
Table 2. Almost one-fourth of the study sample reported
taking at least one psychotropic medication (n = 614, 23%).
Among those who reported any psychotropic medication
use, the most common category was antidepressant use
(15%), followed by anxiolytic use (8%). Among patients with
celiac disease, 23.9% used any psychotropic medication,
compared to 21.8% of controls (p = 0.12). After controlling
for age and sex, celiac disease was not significantly associ-
ated with any psychotropic medication use (OR 1.16; 95%
CI 0.96–1.39; p = 0.12). This null relationship remained
when restricted to males (OR 1.27; 95% CI 0.87–1.87,
p = 0.22), females (OR 1.15; 95% CI 0.92–1.43, p = 0.
23), those aged 18–50 years (OR 1.20; 95% CI 0.93–1.
55, p = 0.16), and those aged ≥51 years (OR 1.07; 95% CI
0.82–1.40, p = 0.61).
Antidepressant use was more common in patients with
celiac disease (16.4%) than controls (13.4%) on univariate
analysis (p = 0.03), an association that remained significant
on multivariate analysis when adjusting for age and sex
(OR 1.28; 95% CI 1.03–1.59; p = 0.03). However, after
removing tricyclic antidepressants (n = 32) from the anti-
depressant category, antidepressant use was not more
common in patients with celiac disease compared to con-
trols on both univariate (CD: 193 (14.9%) vs Controls: 174
(12.4%), p = 0.06) and multivariate analysis (OR 1.23; 95%
CI 0.98–1.54, p = 0.07). The null relationship between
celiac disease and overall psychotropic use remained when
tricyclic antidepressants were removed from the overall
psychotropic medication use category (CD 295 (22.8%) vs
Controls 297 (21.2%), p = 0.13). All other psychotropic
medication categories were not statistically significant on
univariate or multivariate analysis.
On multivariate analysis of factors independently associ-
ated with psychotropic medication use (Table 3), females
(irrespective of celiac disease status) were more likely to
use psychotropic medications (OR 1.41; 95% CI 1.15–1.73,
p = 0.001). Patients older than 50 were also more likely to
use these medications compared to younger patients (OR
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for 51–59: 1.36; 95% CI 1.01–1.84, p = 0.05; OR for ≥60: 1.
37; 95% CI 1.04–1.80, p = 0.03).
Analysis of variables associated with psychotropic medi-
cation use among those with celiac disease is shown in
Table 4. Among celiac disease patients, neither age nor sex
was associated with psychotropic medication use on univar-
iate analysis and multivariate analysis. Among patients for
whom disease duration was known (n = 556) and for whom
mode of presentation was known (n = 689), we tested these
variables for an association with psychotropic medication
use. Neither duration of celiac disease nor mode of presen-
tation was associated with psychotropic medication use on
univariate or multivariate analysis. A comparison of psycho-
tropic medication use in celiac disease patients with a
new diagnosis (prior to, or within 1 month of starting
the gluten-free diet) compared to those who were pre-
viously diagnosed (greater than 1 month) also revealed
no association (new diagnosis: 13 (17.1%) vs previous
diagnosis: 109 (22.7%), p = 0.1).
In a post-hoc analysis, we examined whether antidepres-
sant use was associated with celiac disease duration, and
found that antidepressant use was more common among
those with five or more years of illness compared to those
with four or fewer years of illness (18.15% vs 10.84%, p =
0.014). However, time since diagnosis was not significant
on multivariate analysis (compared to newly-diagnosed
patients, 6 months - 1.99 years: OR 0.82; 95% CI 0.30–2.
25; 2–4.99 years: OR 0.65; 95% CI 0.28–1.54; ≥5 years OR
1.54; 95% CI 0.75–3.15).
Discussion
We found no significant difference in psychotropic medica-
tion use between celiac disease patients and controls. Use
of these medications was common in our sample, reported
by 23.9% of patients with celiac disease and 21.8% of
controls (p = 0.12). When categories of psychotropic med-
ications were analyzed, we found that antidepressant use
was more common among those with celiac disease
Table 1 Characteristics of study patients
Clinical Characteristics Total
(n = 2694) (%)
Celiac Disease
(n = 1293) (%)
Controls
(n = 1401) (%)
P value
Age (in years)
Mean age (± SD) 48.37 (± 17.3) 44.87 (± 17.0) 51.60 (± 17.0) < 0.0001
18–30 534 (19.2) 238 (26.1) 196 (14.0) < 0.0001
31–40 451 (16.7) 240 (18.6) 211 (15.1)
41–50 457 (17.0) 217 (16.8) 240 (17.1)
51–59 464 (17.2) 205 (15.9) 259 (18.5)
≥ 60 788 (29.3) 293 (37.2) 495 (35.3)
Sex
Males 823 (30.6) 352 (27.2) 471 (33.6) 0.0003
Females 1871 (69.5) 941 (72.8) 930 (66.4)
Procedure Indication
Celiac Disease (cases) 1293 (48.0)
Abdominal pain (controls) 811 (30.1)
GERD (controls) 590 (21.9)













Any 614 (22.8) 309 (23.9) 305 (21.8) 0.12 1.16 (0.96–1.39) 0.12
Antidepressants 399 (14.8) 212 (16.4) 187 (13.4) 0.03 1.28 (1.03–1.59) 0.03
Anti-psychotics 48 (1.8) 18 (1.4) 30 (2.1) 0.14 0.65 (0.36–1.19) 0.16
Sleep Aids 84 (3.1) 41 (3.2) 43 (3.1) 0.88 1.12 (0.72–1.75) 0.60
Mood Stabilizers 47 (1.7) 20 (1.6) 27 (1.9) 0.45 0.76 (0.42–1.37) 0.35
Sympathomimetics 65 (2.4) 33 (2.6) 32 (2.3) 0.65 0.94 (0.57–1.55) 0.79
Anxiolytics 210 (7.8) 100 (7.7) 110 (7.9) 0.91 1.07 (0.80–1.43) 0.65
*Adjusted for age and sex
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(p = 0.03). To our knowledge this is the first study to
measure psychotropic medication use among patients
with celiac disease, and the largest study of celiac disease
patients in the United States to investigate psychiatric
disorders (see Table 5).
Antidepressant use was found in 16% of celiac disease
patients, falling within the previously reported wide range
(6–57%) of depression prevalence in celiac disease [4–12].
There is much debate about whether celiac disease is
linked to depression, with some studies reporting a posi-
tive association [4–6, 8, 9, 11, 13–19] and others finding
no such association [7, 10, 20–22]. This relationship is
complicated by studies showing similar rates of depression
in celiac disease compared to other chronic diseases, such
as diabetes [9], irritable bowel syndrome [10], and inflam-
matory bowel disease [13, 21]. In fact, one recent meta-
analysis concluded that celiac disease patients are more
likely to be depressed compared to healthy controls but
are just as likely to be depressed when compared to pa-
tients with chronic conditions [18]. As our control group
was composed of non-celiac patients who nevertheless
had symptoms that necessitated endoscopic evaluation,
our control group are not an entirely healthy group. Des-
pite this, the rates of antidepressant use in our control
group (13.4%) matched the 13% use among the general
US population [31], possibly reflecting a true increased
association between antidepressant use and celiac disease
in our study.
Any positive association between celiac disease and de-
pression could be the result of autoimmune alterations in
neurotransmitter pathways [5, 32], malabsorption of meta-
bolic precursors such as tryptophan, folic acid, and B-12
[28, 29, 32] or perhaps due to reduced quality of life and
illness burden caused by adherence to a gluten free diet
[32, 33]. In our study, celiac patients who had five or more
years of illness were more likely to use antidepressants
compared to those who had four or less years of illness.
This suggests a potential role between illness burden, pos-
sibly due to duration of treatment with the gluten free
diet, and use of antidepressants. However, this relationship
Table 3 Multivariate analysis of age and sex Associated with
use of any Psychotropic Medication*
Variable OR 95% CI p value
Age (in years)
18–30 1.00 – –
31–40 1.07 0.79–1.47 0.66
41–50 1.28 0.94–1.74 0.11
51–59 1.36 1.01–1.84 0.05
≥ 60 1.37 1.04–1.80 0.03
Sex
Males 1.00 – –
Females 1.41 1.15–1.73 0.001
*Adjusted for age and sex
Table 4 Univariate and multivariate analysis of factors associated with Psychotropic use among patients with Celiac Disease









Mean age (±SD) 45.35 (± 16.2) 44.72 (± 17.3) 0.57
18–30 68 (20.1) 270 (79.9) 0.06 1.0 –
31–40 60 (25.0) 180 (75.0) 0.71 (0.35–1.47) 0.36
41–50 54 (24.9) 163 (75.1) 1.21 (0.65–2.25) 0.55
51–59 63 (30.7) 142 (69.3) 1.19 (0.63–2.27) 0.60
≥ 60 64 (21.8) 229 (78.2) 0.77 (0.42–1.43) 0.41
Sex
Males 74 (21.0) 278 (79.0) 0.14 1.0 –
Females 235 (25.0) 706 (75.0) 1.61 (0.99–2.61) 0.05
Duration of celiac disease (n = 556)
Newly diagnosed (0–6 months) 16 (18.2) 72 (81.8) 0.14 1.0 –
6 months - 1.99 years 16 (25.8) 46 (74.2) 1.60 (0.72–3.53) 0.25
2–4.99 years 22 (16.2) 114 (83.8) 0.86 (0.42–1.76) 0.67
≥ 5 years 68 (25.2) 202 (74.8) 1.44 (0.77–2.72) 0.26
Mode of Presentation (n = 689)
Classical 62 (23.5) 202 (76.5) 0.35 1.40 (0.92–2.13) –
Non-classical/silent 87 (20.5) 338 (79.5) 1.0 0.11
*Adjusted for age and sex
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did not reach significance on multivariate analysis. As we
did not examine rates of antidepressant use before and
after the diagnosis of celiac disease or compliance with a
gluten free diet, we could not quantify if symptom burden
or treatment burden played a role in these increased rates.
The literature exploring the relationship between celiac
disease and bipolar disorder is scarce and conflicting. This
may be due to the difficulty in diagnosing bipolar disorder
given that the disease encompasses a spectrum of depres-
sive and manic symptoms and screening questionnaires
have low specificity [32, 34]. In 2007, a population based
cohort study performed by Ludvigsson et al. found no in-
creased risk of bipolar disorder among 13,776 patients with
celiac disease (HR 1.1; 95% CI 0.7–1.7), though they did
find an increased risk of celiac disease among patients with
pre-existing bipolar disorder (OR 1.7; 95% CI 1.2–2.3) [17].
In 2009, a case control study by Garud et al. also found no
difference in the prevalence of bipolar disorder in 600 pa-
tients with celiac disease (2.0%) compared to 200 healthy
controls (0.5%, p = 0.31) [10]. However, a 2015 study by
Carta et al., found a higher prevalence of bipolar disorder
in patients with celiac disease compared to controls: 4.3%
of 60 patients with celiac disease had bipolar disorder
compared to 0.4% of 240 controls (p < 0.005) [19]. While
Ludvigsson et al. and Garud et al. used diagnostic codes to
identify patients with bipolar disorder [10, 17], Carta et al.
used clinical interviews, which may be more accurate [19].
In our study, we found no difference in use of mood stabi-
lizers, which are often prescribed to treat bipolar disorder,
among our 1293 patients with celiac disease compared to
controls (OR 0.76; 95% CI 0.42–1.37). Nevertheless,
our study may have underestimated the true number of
patients with bipolar disorder because of its reliance on
psychotropic medication use. For example, patients with
undiagnosed bipolar disorder may first experience depres-
sion and be treated with antidepressants and only later in
the course of their illness experience the manic symptoms
necessary for a diagnosis of bipolar disorder and subse-
quent treatment with mood stabilizers. More evidence is
necessary to determine if the risk of bipolar disorder is in-
creased among patients with celiac disease.
Our study found no association between anxiolytic use
and celiac disease. The lack of association between anxiety
and celiac disease has been previously reported [7, 10, 18].
Studies reporting a positive association have measured
subtypes of anxiety disorders, specifically subtypes related
to interacting in social situations, such as social phobia
[15] and panic disorder [5, 19]. Furthermore, patients with
celiac disease report state anxiety [4, 13, 15], the symptom
of feeling anxious temporarily, and not trait anxiety
[13, 15, 23], an enduring personality trait of anxiety [35].
As our study did not use questionnaires, we could not
assess the reason for anxiolytic use and any relationship
between anxiety and social situations related to food.
The lack of association between overall psychotropic
medication and celiac disease could be due to the makeup
of our control group, who underwent EGD for either
abdominal pain or GERD. It is possible that celiac disease
patients have similar rates of overall psychotropic medica-
tion use compared to patients with symptoms that war-
rant comprehensive medical investigations, such as our
control population. This would suggest that symptoms of
illness play a role in subsequent diagnosis of depression.
However, we found no link between psychotropic medica-
tion use and mode of presentation of celiac disease, which
demonstrates that gastrointestinal symptoms may not be
driving psychiatric illness or medication use. This lack
of association between gastrointestinal symptoms and
psychiatric illness was reported in a study where patients
with celiac disease and non-celiac gluten sensitivity were
exposed to three days of gluten [36]. While both groups
experienced abdominal pain, both lacked evidence of de-
pression and anxiety [36]. A second possibility for the simi-
lar rates of psychotropic medication use in both groups,
could be that individuals with psychiatric problems are
more likely to seek healthcare for their complaints and are
subsequently more likely to undergo diagnostic testing for
other medical conditions.
Another possibility for our null findings is that patients
with celiac disease might have higher rates of psychiatric
conditions but are less likely to take medications. As the
only treatment for celiac disease is a non-pharmacologic
diet, patients may be more likely to opt for non-
pharmacologic treatments for their illnesses. Patients
with celiac disease use less painkillers, sleep aids, and
medicines for dyspepsia and more vitamins, micronu-
trients, and herbal products after being diagnosed with
celiac disease compared to before diagnosis [37]. Patients
with celiac disease may therefore have psychiatric disorders
that are not fully treated as suggested in a recent study that
found an increased risk of suicide in patients with celiac
disease, even after adjusting for lifetime depressive disorder,
anxiety disorder, and any psychiatric disorder [38].
Our study has several limitations. Firstly, as we relied
on medication use rather than a validated instrument to
establish a psychiatric diagnosis, we did not identify
patients who were experiencing symptoms without using
medications. Similarly, as many psychotropic medications
can be used for multiple psychiatric diagnoses, medication
use may not completely correlate with a specific psychiatric
diagnosis. Secondly, though performance in a tertiary care
center contributed to our large sample size of celiac disease
patients, it is possible that this may have led to selection
bias. The patients who seek out a tertiary center may have
different characteristics, including use of psychotropic med-
ications, compared to those in primary care facilities. How-
ever, we believe our control group is a useful comparator as
it accounted for the presence of gastrointestinal symptoms
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and evaluation of these symptoms by invasive procedures
in our two groups. We adjusted for age and sex in our
statistical analysis, but we were not able to adjust for
other possible confounders such as race or socioeconomic
status as this was unavailable in our endoscopy record.
We did limit our sample to patients who underwent en-
doscopies performed by the six physicians at the celiac
disease center during a 9-year time period in order to
eliminate any disparity in physician access or demographic
factors that may have existed between our celiac disease
and control groups. Furthermore, our findings concern
only diagnosed celiac disease and do not necessarily apply
to undiagnosed (and untreated) celiac disease. Finally, as
we lacked patients’ comorbid conditions we could not
explore the relationship between psychiatric illness celiac
disease, and chronic medical conditions, which have been
previously reported [9, 10, 13, 18, 21].
Conclusions
Our study found no significant association between use
of psychotropic medications in patients with celiac dis-
ease compared to a control group undergoing EGD for
abdominal pain or GERD. People suffering from celiac
disease may be comforted by the knowledge that they are
not more likely to use psychotropic medications compared
to other people experiencing gastrointestinal complaints.
Our finding of an increased risk of antidepressant use
among celiac disease patients raises the possibility that
a pathophysiologic feature of the disease or a feeling of
treatment burden predisposes to depression in the celiac
disease population. Future studies should investigate
psychiatric conditions in celiac disease using validated
measures of psychiatric illness so as to determine the
prevalence of these conditions and whether they are re-
lated to the adoption of the gluten-free diet.
Appendix
Classification of psychotropic medications into sub-categories
The following were classified as antidepressants: amitriptyl-
ine/elavil, bupropion/wellbutrin, citalopram/celexa, duloxe-
tine/cymbalta, desipramine, desvenlafaxine/pristiq doxepin,
escitalopram/lexapro, fluoxetine/prozac, fluvoxamine,
mirtazapine/remeron, nortriptyline, paroxetine/paxil,
milnacipran/savella, sertraline/zoloft, topramine, trazadone,
and venlafaxine/effexor; as anti-psychotics: aripiprazole/
abilify, droperidol, haloperidol/haldol, olanzapine/zyprexa,
paliperidone/invega, prochlorperazine/compazine, risperi-
done/resperdal, trifluoperazine/stelazine, and questiapine/
seroquel; as anti-anxiolytics: alprazolam/tafil/xanax,
busiporone/buspar, clonazepam/klonopin, diazepam/valium,
lorazepam, midazolam/versed, norazapam/ativan, pheno-
barbital, temazepam, and triazolam/halcion; as mood
stabilizers: lithium/lithobid, carbamazepine/tegretol, topir-
amate/Topamax/topiramax, and valproic acid/Depakote/
divalproex sodium; as sleep aids: dextromethorphan- dox-
ylamine succinate/nyquil, eszapiclone/lunesta, ibuprofen-
diphenhydramine/advil pm, naproxen- diphenhydramine/
aleve pm, melatonin, and zolpidem/ambien/edluar;
and as sympathomimetics: amphetamine/dextroamphet-
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